Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director · President, CEO and Interim CFO | April 24, 2026 | April 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MUSTANG BIO, INC.
Report date April 24, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 1,615 |
Reported balance
After 2026-04-24 transaction · row 1
1 source rowRow 1 · 2026-04-24 · Tax withholding · Disposed 19 · Balance 1,615 F1: 19 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: 19 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2026 Filed Apr 27, 2026 20:05 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | Tax withholdingCOMMON STOCK | 19 | $0.75 | $14.25 |
DisclosureSEC source: 0001104659-26-049430 · tm2612756-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President, CEO and Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,615 F1 · shares: 19 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. Read SEC document |
| April 24, 2025 Filed Apr 28, 2025 20:30 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | Tax withholdingCOMMON STOCK | 27 | $1.24 | $33.48 |
DisclosureSEC source: 0001104659-25-040237 · tm2513385-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President, CEO and Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,634 F1 · shares: 27 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. F2 · balance_after: Effective January 15, 2025, the Issuer effected a one-for-fifty reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 31, 2024 Filed Jun 5, 2024 00:35 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | Tax withholdingCommon Stock | 1,396 | $0.35 | $488.60 |
DisclosureSEC source: 0001104659-24-068411 · tm2416466-2_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,024 F1 · shares: 1,396 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. F2 · balance_after: Includes 5,000 shares of common stock acquired under the Mustang Bio, Inc. Employee Stock Purchase Plan on March 1, 2024. Read SEC document |
| April 24, 2023 Filed Jul 7, 2023 20:06 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-079110 · tm2320790-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,079 F1 · shares: Represents an award of 5,000 restricted stock units that will vest in four annual installments after the grant date, vesting in full on April 24, 2027. F2 · shares: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| April 24, 2023 Filed Jun 5, 2024 00:33 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | Tax withholdingCommon Stock | 1,572 | $4.21 | $6,618.12 |
DisclosureSEC source: 0001104659-24-068409 · tm2416466-1_4seq1.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,420 F3 · shares: 1,572 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. Read SEC document |
| September 13, 2022 Filed Apr 3, 2023 20:51 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 5,000 | $0.52 | $2,582.00 |
DisclosureSEC source: 0001104659-23-040934 · tm2311237d6_4seq1.xml · nonDerivative · entry 3 Litchman Manuel MD · CIK 0001709485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,098,987 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| June 21, 2022 Filed Apr 3, 2023 20:51 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-040934 · tm2311237d6_4seq1.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,093,987 F3 · shares: Represents an award of 61,000 restricted stock units that will vest in four annual installments after the grant date, vesting in full on April 24, 2026. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| April 24, 2022 Filed Jun 5, 2024 00:33 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | Tax withholdingCommon Stock | 1,248 | $12.15 | $15,163.20 |
DisclosureSEC source: 0001104659-24-068409 · tm2416466-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,992 F1 · shares: 1,248 shares of common stock were relinquished to cover tax liability associated with the delivery of shares of common stock upon the vesting of restricted stock units. F2 · balance_after: The amount of common stock reflected on this Form 4 has been adjusted to reflect a 1-for-15 reverse stock split that occurred subsequent to this transaction. F4 · balance_after: Includes 3,975 shares of common stock acquired under the Mustang Bio, Inc. Employee Stock Purchase Plan on March 1, 2023 and September 1, 2023. Read SEC document |
| March 18, 2022 Filed Apr 3, 2023 20:51 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK, PAR VALUE $0.0001 | 5,000 | $0.74 | $3,695.00 |
DisclosureSEC source: 0001104659-23-040934 · tm2311237d6_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,987 F1 · shares: Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| October 27, 2021 Filed Nov 8, 2021 21:35 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 65,000 | $2.24 | $145,600.00 |
DisclosureSEC source: 0001104659-21-135706 · tm2132286-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,987 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the purchase transactions on October 27, 2021, was $2.22 to $2.26. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| August 31, 2021 Filed Sep 24, 2021 21:23 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 2,746 | $2.58 | $7,084.68 |
DisclosureSEC source: 0001104659-21-119384 · tm2128458-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,987 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2021 and ending on August 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on August 31, 2021 (the purchase date of the offering period). F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 30, 2021 Filed Aug 5, 2021 20:23 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 86,206 | $2.91 | $250,859.46 |
DisclosureSEC source: 0001104659-21-100783 · tm2124277-1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,241 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the purchase transactions on July 30, 2021, was $2.89 to $2.94. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| June 17, 2021 Filed Jul 8, 2021 20:31 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-090242 · tm2121675-3_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,035 F1 · shares: Each restricted stock unit represents the right to receive one share of Common Stock of Mustang Bio, Inc. The restricted stock units will vest at different times over a period of 4 years. F2 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| March 05, 2021 Filed Mar 15, 2021 10:35 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 165,562 | $3.12 | $516,553.44 |
DisclosureSEC source: 0001104659-21-035857 · tm219639d1_4seq1.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,408 F2 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the purchase transactions on March 5, 2021, was $3.01 to $3.177. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| February 26, 2021 Filed Mar 15, 2021 10:35 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 5,000 | $2.83 | $14,150.00 |
DisclosureSEC source: 0001104659-21-035857 · tm219639d1_4seq1.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,846 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2020 and ending on February 28, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on September 1, 2020 (the purchase date of the offering period). F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| December 15, 2020 Filed Dec 22, 2020 21:18 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 100,000 | $2.91 | $291,000.00 |
DisclosureSEC source: 0001104659-20-138581 · tm2039180-1_4.xml · nonDerivative · entry 3 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,846 F4 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the purchase transactions on December 15, 2020, was $2.85 to $2.98. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| September 15, 2020 Filed Dec 22, 2020 21:18 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138581 · tm2039180-1_4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,846 F3 · shares: 61,000 shares are restricted share units which vest over various time periods. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| August 31, 2020 Filed Dec 22, 2020 21:18 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001104659-20-138581 · tm2039180-1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,846 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2020 and ending on August 31, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the purchase date of the offering period). F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:32 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCOMMON STOCK | 153,846 | $3.25 | $499,999.50 |
DisclosureSEC source: 0001104659-20-073411 · tm2022538-1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,846 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 22, 2020 Filed Apr 29, 2021 20:31 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | SaleCOMMON STOCK | 8,348 | $3.04 | $25,377.92 |
DisclosureSEC source: 0001104659-21-057674 · tm2113475d1_4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,035 F2 · kind: 8,348 shares were sold in connection with the vesting of 30,500 shares on April 24, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Litchman's tax withholding obligations. Mr. Litchman had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average sales price. F4 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 22, 2020 Filed Apr 29, 2021 20:31 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | SaleCOMMON STOCK | 4,025 | $3.04 | $12,236.00 |
DisclosureSEC source: 0001104659-21-057674 · tm2113475d1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,383 F1 · kind: 4,025 shares were sold in connection with the vesting of 15,250 shares on March 26, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Litchman's tax withholding obligations. Mr. Litchman had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average sales price. F4 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 21, 2020 Filed May 22, 2020 23:07 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 90,000 | $3.13 | $281,700.00 |
DisclosureSEC source: 0001104659-20-065513 · tm2020825d1_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 14, 2020 Filed May 22, 2020 23:07 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 90,000 | $2.79 | $251,100.00 |
DisclosureSEC source: 0001104659-20-065513 · tm2020825d1_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 26, 2020 Filed Apr 29, 2020 12:48 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 122,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-052884 · tm2018004-2_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 F2 · shares: Each restricted stock unit represents the right to receive one share of Common Stock of Mustang Bio, Inc. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 05, 2020 Filed Apr 29, 2020 12:48 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001104659-20-052884 · tm2018004-2_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2019 and ending on February 29, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the last trading day of the offering period). Read SEC document |
| December 10, 2018 Filed Dec 18, 2018 21:59 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 8,000 | $3.35 | $26,804.80 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 5 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2018 Filed Dec 18, 2018 21:59 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 7,500 | $3.60 | $27,000.00 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 4 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| November 26, 2018 Filed Dec 18, 2018 21:59 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 5,000 | $3.87 | $19,353.50 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 3 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 21, 2018 Filed Dec 18, 2018 21:59 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 5,000 | $4.21 | $21,048.00 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 20, 2018 Filed Dec 18, 2018 21:59 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | PurchaseCommon Stock | 2,500 | $3.89 | $9,720.25 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.